Guardium Acid Reflux Control (Esomeprazole)

Guardium Acid Reflux Control is indicated for the treatment and maintenance of several acid‑related gastrointestinal disorders. Clinical use focuses on conditions where excess gastric acid contributes to symptoms or tissue damage.

• Gastro‑oesophageal reflux disease (GERD) with persistent heartburn or regurgitation.
• Healing of erosive oesophagitis confirmed by endoscopy.
• Maintenance therapy to prevent recurrence of GERD symptoms after initial healing.
• Relief of heartburn that occurs frequently (two or more days per week) in adults.
• Adjunctive treatment for Zollinger‑Ellison syndrome when acid suppression is required.

Side‑effect profiles for Guardium Acid Reflux Control reflect those typical of esomeprazole and other proton‑pump inhibitors. Most patients experience mild, transient symptoms, while serious reactions are uncommon.

Common

• Headache
• Diarrhoea or loose stools
• Nausea or abdominal discomfort
• Flatulence or bloating

Serious

• Severe allergic reaction with rash, itching, swelling, or difficulty breathing
• Low magnesium levels leading to muscle cramps or irregular heartbeat
• Clostridioides difficile infection presenting as persistent diarrhoea
• Liver enzyme elevations indicating possible hepatic involvement

Before starting Guardium Acid Reflux Control, certain health considerations should be reviewed to ensure safe use and to minimise potential risks.

• Assess for known hypersensitivity to esomeprazole or other proton‑pump inhibitors.
• Use cautiously in patients with severe liver disease, as drug clearance may be reduced.
• Evaluate the need for long‑term therapy, since prolonged use can increase fracture risk.
• Monitor magnesium levels during extended treatment, especially in the elderly.
• Consider alternative management for patients with a history of C. difficile infection.
• Discuss pregnancy and breastfeeding status with a healthcare professional, as safety data are limited.

Guardium Acid Reflux Control may affect the absorption or metabolism of other medicines. Identifying potential interactions helps to avoid reduced efficacy or increased toxicity.

Avoid

• Concomitant use with atazanavir or other protease inhibitors that require acidic gastric pH for absorption.
• Co‑administration with methotrexate high‑dose regimens, which can raise methotrexate levels.

Use with caution

• Antiplatelet agents such as clopidogrel, where reduced activation may lessen antithrombotic effect.
• Warfarin, because altered gastric pH can affect INR stability.
• Digoxin, as decreased absorption may occur.
• Certain antifungal agents (e.g., ketoconazole, itraconazole) that rely on acidic conditions for optimal absorption.